Agenus’ lead cancer vaccine flops, investigators read last rites over glioblastoma PhII
Just days after handing over the reins on a big antibody collaboration to Incyte, Agenus is now slamming the brakes on its top cancer vaccine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
